Syneron Launches its Proprietary Sublative Technology for Acne Scars

     Syneron Launches its Proprietary Sublative Technology for Acne Scars

  PR Newswire

  YOKNEAM, Israel, April 4, 2013

YOKNEAM, Israel, April 4, 2013 /PRNewswire/ --

 New "Skinhibitions™" consumer marketing campaign to increase awareness about
 its proprietary Sublative™ technology offered in the eMatrix, eTwo and elos
          Plus Systems for both skin rejuvenation and now acne scars

Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device
company, announced today that it will begin the market launch of its
proprietary Sublative technology for the removal or modification of the
appearance of acne scars. The acne scar treatment is available on all of the
Syneron Sublative compatible systems, which includes elōs Plus™, eTwo™ and
eMatrix™.

 (Logo: http://photos.prnewswire.com/prnh/20120528/535447 )

 (Photo: http://photos.prnewswire.com/prnh/20130404/606753 )

Acne is the most common skin disorder in the United States, affecting 40 to 50
million Americans. By mid-teens, more than 40 percent of adolescents have acne
or acne scarring, which requires treatment by a dermatologist. ^[1] Syneron's
Sublative technology is the only bi-polar fractional radiofrequency (RF)
energy device proven to effectively treat acne scars. Due to its unique
design, energy can now be delivered beneath the surface of the skin to
maximize collagen production while preserving the top layer of the skin
intact. This means patients benefit from significant results without the down
time or potential complications of more aggressive treatments. 

"As an early adopter of the Sublative technology it's been a real delight to
have been at the forefront of this revolutionary technology and see it evolve
to serve as my staple treatment for my acne scar patients," said Michael Gold,
M.D., board certified dermatologist and Medical Director at the Gold Skin Care
Center in Nashville, Tennessee. "While there are nonsurgical to surgical
methods to treating a wide range of superficial to defused acne scars, my
go-to-treatment is Sublative due to its exceptional results, minimal downtime
and unmatched safety profile."

In conjunction with the new acne scar treatment, Syneron will introduce
"Skinhibitions" - a new focused consumer marketing campaign based on market
research the company completed which showed that a majority of women were
interested in more efficacious skin procedures but were inhibited by fear of
pain, significant down time, side effects and high cost. In an online survey
commissioned by Syneron, 22 percent of adults 18 years and older considered
acne scars to be an issue that they would like to do something about. Of the
respondents that have acne scars, 77 percent responded that they would like to
seek a treatment but are inhibited by high costs, pain, downtime and lack of
results. Importantly, this survey also indicated more than half of these
patients would seek more information about Sublative technology.

"I chose to have my acne scars treated because I felt when people looked at me
they didn't see the real me, they just saw my scars," stated Katelyn Baker, a
patient of the Gold Skin Care Center in Nashville, Tennessee. "I've had two
pain-free treatments with Sublative and my skin is smoother, more filled out,
and has a natural glow. I am now more confident and feel that people are
focusing on me now instead of looking at my scars."

--------------------------------------------------

1. http://www.aad.org/media-resources/stats-and-facts/conditions/acne

Louis Scafuri, Chief Executive Officer of Syneron, said, "We have received
very positive physician and patient feedback on the Sublative technology since
its introduction in 2009. This fractional bi-polar radio frequency technology
delivers excellent results with little-to-no downtime and is a safe and more
effective treatment alternative for all skin tones. The addition of an acne
scar treatment further expands its clinical utility and will allow our
customers to address a large and underserved segment of the aesthetic market.
We look forward to supporting the expanded treatment with the launch of our
"Skinhibitions" focused consumer marketing campaign, which will help increase
awareness of the excellent results that can be achieved in treating acne scars
with the Sublative technology."

Syneron will introduce the new acne scar treatment for its Sublative
compatible platforms and its new "Skinhibitions" consumer campaign at the
American Society of Laser Medicine & Surgery annual conference in Boston,
Massachusetts from April 3-7, 2013 and at the Anti-Aging Medicine World
Congress & Medispa in Monte-Carlo, Monaco from April 4-6, 2013.

About Syneron Medical Ltd.

Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device
company with a comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to provide advanced
solutions for a broad range of medical-aesthetic applications including body
contouring, hair removal, wrinkle reduction, rejuvenation of the skin's
appearance through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite. The Company sells
its products under two distinct brands, Syneron and Candela. Founded in 2000,
the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd.
are located in Israel. Syneron also has R&D and manufacturing operations in
the US. The Company markets, services and supports its products in 90
countries. It has offices in North America, France, Germany, Italy, Portugal,
Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

Any statements contained in this document regarding future expectations,
beliefs, goals, plans or prospects constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Further, any statements that are not statements of historical fact (including
statements containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions) should also
be considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements, including
the risk that the businesses of Syneron and Candela may not be integrated
successfully; the risk that the merger transaction with Candela may involve
unexpected costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to realize
than expected; the risk that disruptions from the merger transaction make it
more difficult to maintain relationships with customers, employees, or
suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most
recent Annual Report on Form 20-F, and the other factors described in the
filings that Syneron Medical Ltd. makes with the SEC from time to time. If one
or more of these factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or achievements
may vary materially from any future results, performance or achievements
expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and
beliefs of Syneron Medical Ltd. as of the date of this document. Syneron
Medical Ltd. anticipates that subsequent events and developments will cause
its expectations and beliefs to change. However, while Syneron Medical Ltd.
may elect to update these forward-looking statements publicly in the future,
it specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential impact of any
future dispositions or strategic transactions that may be undertaken. These
forward-looking statements should not be relied upon as representing Syneron
Medical Ltd.'s views as of any date after the date of this document.

Contacts: Syneron Public Relations pr@syneron.com

Hugo Goldman, Chief Financial Officer hugo.goldman@syneron.com

Zack Kubow, The Ruth Group +1-646-536-7020 zkubow@theruthgroup.com


 
Press spacebar to pause and continue. Press esc to stop.